Business Wire

Little Life Hack, “Berry” Big Benefit


Women today do it all and don’t have time to be slowed down by pesky infections like urinary tract infections (UTIs). Luckily, there’s a simple solution to stave off that unwelcome sensation, and it’s been around for nearly a century – cranberry juice. Chock-full of powerful nutrients, cranberries have unique anti-bacterial properties that help prevent the bacteria that cause UTIs from sticking in the body. That’s great news for your busy schedule, and even better for you!

This Smart News Release features multimedia. View the full release here:

A Super Pain
If you think urinary tract infections won’t affect you, think again. According to researchers, approximately 60 percent of women will experience one UTI in their lifetimes and one in four women will suffer a recurrence within six months1, 2.

Urinary tract infections are typically remedied with a course of low-dose antibiotics, but you may not be in the clear even after the infection has passed. That’s because even after treatment, bacteria may still be lurking in the bladder, leaving room for yet another infection – and who has time for that?

A Super Problem
While UTIs may seem like a small problem, they affect 150 million people annually worldwide, making them the second most common type of infection3.

Ocean Spray commissioned studies in Australia and Turkey to understand how UTIs affected quality of life across the regions and found they are truly disruptive. In Australia, 4.8 million working hours are lost each year due to UTIs and contribute to an economic loss of $197 million. More than half (53 percent) of the women surveyed in Turkey said UTIs impacted their everyday life. That number increased to 69 percent for those who experienced a UTI in the last year.

Concurrently, the bacteria that cause UTIs are becoming increasingly resistant to the strongest antibiotics used to treat them. This is fueling a dangerous increase in antibiotic resistance worldwide as this limits the body’s ability to fight off common infections like UTIs. According to the World Health Organization antibiotic resistance is one of the greatest challenges to public health today4.

A Super Fruit, A Super Solution
Despite the reports, there is good news for consumers. Research suggests that consuming cranberries daily may be a nutritional approach to help reduce the recurrence of UTIs and decrease the worldwide use of antibiotics.

How exactly? Up until recently, it was thought the secret to the cranberry’s abilities came from a single component within the fruit, Type-A PACs, that provide an antibacterial effect by preventing bacteria from sticking5, 6. New studies point to a unique combination of compounds in cranberries, including a newly discovered class of compounds, xyloglucan oligosaccharides, which have similar anti-bacterial properties against E. coli as PACs7. This means there are multiple, powerful elements within cranberries working hard for your health.

So the next time you head to the store, consider stocking up on cranberry juice – one 8-ounce glass (236 mL) of cranberry juice or ¼ cup (40 g) of dried cranberries daily could be one of the best ways to prevent irksome infections like UTIs.

About Cranberry Health Benefits

For more than 85 years, we have been actively researching the cranberry’s unique healthy benefits to deliver products that not only taste good, but are good for you. Cranberries are an exceptional fruit that provide one-of-a-kind health benefits. Besides helping consumers meet the recommended daily intake of fruit, consuming cranberries may be a nutritional approach in helping to reduce certain infections in the urinary tract and stomach. This is increasingly important as the bacteria that cause these infections are becoming highly resistant to the strongest antibiotics used to treat them, fueling what the World Health Organization believes is one of the greatest challenges to public health today – antibiotic resistance.

About Ocean Spray

Ocean Spray is a vibrant agricultural cooperative owned by more than 700 cranberry and grapefruit growers in the United States, Canada and Chile who have helped preserve the family farming way of life for generations. Formed in 1930, Ocean Spray is now the world’s leading producer of cranberry juices, juice drinks and dried cranberries and is the best-selling brand in the North American bottled juice category. The cooperative’s cranberries are currently featured in more than a thousand great-tasting, good-for-you products in over 100 countries worldwide. With more than 2,000 employees and nearly 20 cranberry receiving and processing facilities, Ocean Spray is committed to managing our business in a way that respects our communities, employees and the environment. For more information visit: or

1 Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am 2014;28:1–13.
2 Wang CH, Fang CC, Chen NC, Liu SS, Yu PH, Wu TY, Chen WT, Lee CC, Chen SC. Cranberry-containing products for prevention of urinary tract infections in susceptible populations: a systemic review and meta-analysis of randomized controlled trials. Arch Intern Med 2012;172:988–96.
3 American Urological Association. “Adult UTI: Epidemiology/Socioeconomics/Education.” Available at:
4 Antimicrobial resistance: global report on surveillance 2014; WHO;
5 Howell AB, Reed JD, Krueger CG, Winterbottom R, Cunningham DG, Leahy M. A-type cranberry proanthocyanidins and uropathogenic bacterial anti-adhesion activity. Phytochemistry, 2005; 66(18): 2281-2291.
6 de Llano DG, Esteban-Fernández A, Sánchez-Patán F, Martínlvarez PJ, Moreno-Arribas MV, Bartolomé B. Anti-Adhesive Activity of Cranberry Phenolic Compounds and Their Microbial-Derived Metabolites against Uropathogenic Escherichia coli in Bladder Epithelial Cell Cultures. Int J Mol Sci. 2015 May 27;16(6):12119-30.
7 Hotchkiss AT, Nunez A, Strahan GD, Chau H, White A, Marais J, Hom K, Vakkalanka MS, Di R, Yam KL, Khoo C. Cranberry Xyloglucan Structure and Inhibition of Escherichia coli Adhesion to Epithelial Cells. J Agric Food Chem. 2015 Jun 17;63(23):5622-33.

Contact information

Weber Shandwick for Ocean Spray
Kelly Vesty, 617-520-7061

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 18:28Pressemelding

Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (, a leading German electronics publication. This press release features multimedia. View the full release here: Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl

Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05Pressemelding

Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52Pressemelding

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50Pressemelding

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00Pressemelding

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on